For instance, the post hoc analysis of the CheckMate 032 study indicated that CD8 + T cell infiltration ≥ 1% was correlated with better survival in relapsed SCLC patients receiving nivolumab monotherapy (HR, 0.51; 95% CI 0.27–0.95), with a similar trend seen in patients receiving nivolumab plus ipilimumab (HR, 0.7; 95% CI 0.32–1.49) [68]. Here, CD8A is linked to small cell lung carcinoma.